首页|基于胆固醇代谢的复方甘草酸苷片配伍雷公藤多苷片减轻肝损伤机制

基于胆固醇代谢的复方甘草酸苷片配伍雷公藤多苷片减轻肝损伤机制

扫码查看
目的:基于胆固醇代谢,研究雷公藤多苷片(TG)的肝损伤作用机制,及复方甘草酸苷片(CG)配伍TG减轻TG所致胆固醇代谢异常的分子机制。方法:雄性SD大鼠按体质量随机分为正常组(纯净水),TG低、高剂量(TG-L、TG-H)组(TG 189。0、472。5 mg·kg-1·d-1),TG 与复方甘草酸苷片配伍(TG-L+CG、TG-H+CG)组(给药剂量分别为 TG 189。0 mg·kg-1·d-1+CG 20。25 mg·kg-1·d-1和TG 472。5 mg·kg-1·d-1+CG 20。25 mg·kg-1·d-1),每组 6只,共5组。每日给药 1 次,连续3周。末次给药结束后,通过实时荧光定量聚合酶链式反应(Real-time PCR)检测大鼠肝组织内肝X受体-α(LXR-α)、低密度脂蛋白受体(LDLR)、三磷酸腺苷结合盒转运蛋白A1(ABCA1)、三磷酸腺苷结合盒转运蛋白G1(ABCG1)、3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)、胆固醇7α羟化酶(CYP7A1)、胆固醇12α羟化酶(CYP8B1)、甾醇27α羟化酶(CYP27A1)在信使核糖核酸(mRNA)水平的变化;利用蛋白免疫印迹法(Western blot)进一步验证关键蛋白表达水平的变化;通过酶联免疫吸附测定法(ELISA)检测胆固醇合成的调控酶羟甲基戊二酸单酰辅酶A还原酶(HMG-CoAR)的含量。以人肝癌细胞(HepG2)作为体外实验对象,观察TG对HepG2细胞的增殖抑制作用。设置TG提取物低、中、高剂量(TG-1、TG-m、TG-h)组(TG 135、45、15 mg·L-1),非诺贝特(FB)组(10 μmol·L-1)和 CG 提取物组,以及配伍组(TG-h+FB、TG-m+FB、TG-1+FB、TG-h+CG、TG-m+CG、TG-1+CG,给药浓度分别为 TG 135 mg·L-1+FB 10 μmol·L-1、TG 45 mg·L-1+FB 10 μmol·L-1、TG 15 mg·L-1+FB 10 μmol·L-1、TG 135 mg·L-1+CG 60 mg·L-1、TG 45 mg·L-1+CG 60 mg·L-1、TG 15 mg·L-1+CG 60 mg·L-1),通过 Real-time PCR、Western blot检测HepG2细胞内LXR-α、ABCG1、LDLR、CYP7A1、CYP8B1、CYP27A1在mRNA水平及蛋白水平的表达变化,进一步验证CG配伍TG的减毒机制。结果:SD大鼠在体实验,与正常组比较,TG-H组大鼠肝组织CYP7A1、CYP8B1、CYP27A1 mRNA水平明显下降(P<0。05,P<0。01);与CG联合用药后,上述3种mRNA水平明显升高(P<0。05,P<0。01);TG-H+CG组LDLR mRNA水平显著升高(P<0。01)。与正常组比较,TG-L、TG-H组大鼠肝组织LDLR、CYP7A1、CYP8B1蛋白表达水平明显降低(P<0。05,P<0。01),TG-L组ABCG1的蛋白表达水平明显降低(P<0。05),TG-H组LXR-α的蛋白表达明显升高(P<0。05)。TG与CG联合用药,与同等剂量的TG单独用药组比较,配伍组ABCG1、LDLR蛋白表达水平明显升高(P<0。05,P<0。01);TG-H+CG组CYP7A1、CYP8B1的蛋白表达水平明显升高(P<0。05,P<0。01)。HepG2细胞实验,与空白组比较,TG-h组HepG2细胞内LXR-α mRNA水平显著升高(P<0。01);TG-m、TG-h组 LDLR、CYP7A1 mRNA水平显著降低(P<0。01),CYP27A1 mRNA水平显著升高(P<0。01)。TG与CG联合用药,对上述mRNA有显著回调作用(P<0。01)。与空白组比较,TG-m、TG-h组HepG2细胞内 LXR-α、ABCG1、LDLR、CYP7A1、CYP8B1、CYP27A1 蛋白表达水平显著降低(P<0。01)。与 TG-h 组比较,TG-h+CG 组LDLR蛋白表达水平明显升高(P<0。05);与TG-m组比较,TG-m+CG组LDLR、ABCG1、CYP7A1、CYP27A1蛋白表达水平明显升高(P<0。05,P<0。01)。结论:连续3周给予大鼠189。0、472。5 mg·kg-1 TG,可调控肝细胞内胆固醇流出和胞吞及胆固醇生物转化相关信号通路,致使机体内胆固醇累积进而引发肝损伤。CG可通过上调LXR-α、LDLR、ABCG1、CYP7A1、CYP8B1及CYP27A1表达水平,促进胆固醇生物转化,缓解TG致脂质代谢紊乱诱发的肝损伤。
Compound Glycyrrhizin Tablets Ameliorate Liver Injury Induced by Tripterygium Glycosides Tablet by Regulating Cholesterol Metabolism
Objective:To investigate the mechanism of liver injury induced by tripterygium glycosides tablets(TG)and the molecular mechanism of compound glycyrrhizin tablets(CG)in alleviating the abnormalities of cholesterol metabolism caused by TG via cholesterol metabolism.Methods:According to the body weights,male Sprague-Dawley(SD)rats were randomly grouped as follows:control(pure water),low-dose TG(TG-L,189.0 mg·kg-1·d-1),high-dose TG(TG-H,472.5 mg·kg-1·d-1),TG-L+CG(189.0 mg·kg-1·d-1 TG+20.25 mg·kg1·d-1 CG),and TG-H+CG(472.5 mg·kg1·d-1 TG+20.25 mg·kg1·d-1 CG),with 6 rats in each group.Rats were administrated with corresponding drugs once daily for 3 weeks.At the end of the last administration,the mRNA and protein levels of liver X receptor-alpha(LXR-α),low-density lipoprotein receptor(LDLR),adenosine triphosphate-binding cassette transporter A1(ABCA1),adenosine triphosphate-binding cassette transporter G1(ABCG1),3-hydroxy-3-methylglutaryl coenzyme A reductase(HMGCR),cholesterol 7α-hydroxylase(CYP7A1),cholesterol 12α-hydroxylase(CYP8B1),and sterol 27-hydroxylase(CYP27A1)in the liver tissue were determined by Real-time PCR and Western blotting,respectively.The level of 3-hydroxy-3-methylglutaryl coenzyme A reductase(HMG-CoAR),a regulatory enzyme of cholesterol synthesis,was measured by enzyme-linked immunosorbent assay(ELISA).HepG2 cells were used to observe the effect of TG on the cell proliferation in vitro.Specifically,HepG2 cells were grouped as follows:Low-dose TG(TG-1,15 mg·L-1),medium-dose TG(TG-m,45 mg·L-1),high-dose TG(TG-h,135 mg·L1),fenofibrate(FB,10 μmol·L-1),CG extract,TG-h+FB(135 mg·L-1 TG+10 μmol·L-1 FB),TG-m+FB(45 mg·L-1 TG+10 μmol·L-1 FB),TG-l+FB(15 mg·L-1 TG+10 μmol·L-1 FB),TG-h+CG(135 mg·L-1 TG+60 μmol·L-1 CG),TG-m+CG(45 mg·L-1 TG+60 μmol·L-1 CG),and TG-l+CG(15 mg·L-1 TG+60 μmol·L-1 CG).The mRNA and protein levels of LXR-α,ABCG1,LDLR,CYP7A1,CYP8B1,and CYP27A1 in HepG2 cells were determined by Real-time PCR and Western blotting,respectively.Results:The rat experiment showed that compared with the control group,the TG-H group showed down-regulated mRNA levels of CYP7A1,CYP8B1,and CYP27A1 in the liver tissue(P<0.05,P<0.01),which were up-regulated by the application of CG(P<0.05,P<0.01),and the TG-H+CG group showed up-regulated mRNA level of LDLR(P<0.01).Compared with the control group,the TG-L and TG-H groups showed down-regulated protein levels of LDLR,CYP7A1,and CYP8B1 in the liver tissue(P<0.05,P<0.01).In addition,the protein levels of ABCG1 and LXR-α were down-regulated in the TG-H and TG-L groups,respectively(P<0.05).Compared with TG alone,TG+CG up-regulated the protein levels of ABCG1 and LDLR(P<0.05,P<0.01),and the protein levels of CYP7A1 and CYP8B1 in the TG-H+CG group were up-regulated(P<0.05,P<0.01).The cell experiment showed that compared with the control group,the TG-h group presented up-regulated mRNA level of LXR-α(P<0.01),and the TG-m and TG-h groups showcased down-regulated mRNA levels of LDLR and CYP7A1(P<0.01)and up-regulated mRNA level of CYP27A1(P<0.01)in HepG2 cells.The combination of CG with TG restored the above changes(P<0.01).Western blotting results showed that compared with the control group,the TG-m and TG-h groups showed down-regulated protein levels of LXR-α,ABCG1,LDLR,CYP7A1,CYP8B1,and CYP27A1 in HepG2 cells(P<0.01).Compared with the TG-h group,the TG-h+CG group showed up-regulated protein level of LDLR(P<0.05).Compared with the TG-m group,the TG-m+CG group showcased up-regulated protein levels of LDLR,ABCG1,CYP7A1,and CYP27A1(P<0.05,P<0.01).Conclusion:The administration of TG at 189.0,472.5 mg·kg-1 for 3 weeks could modulate the signaling pathways associated with cholesterol efflux,endocytosis,and cholesterol biotransformation in hepatocytes,leading to the accumulation of cholesterol and subsequent liver injury in rats.CG could ameliorate the liver injury induced by lipid metabolism disorders caused by TG by up-regulating the expression of LXR-α,LDLR,ABCG1,CYP7A1,CYP8B1,and CYP27A1 to promote cholesterol biotransformation.

tripterygium glycosides tabletscompound glycyrrhizin tabletsliver injurytoxin reduction by compatibilitycholesterol metabolism

付小桐、曹春雨、李春、卢晨娜、刘婷、杨依霏

展开 >

中国中医科学院中药研究所,北京 100029

雷公藤多苷片 复方甘草酸苷片 肝损伤 配伍减毒 胆固醇代谢

2025

中国实验方剂学杂志
中国中医科学院中药研究所 中国中西医结合学会中药专业委员会

中国实验方剂学杂志

北大核心
影响因子:1.62
ISSN:1005-9903
年,卷(期):2025.31(2)